Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer

World J Gastroenterol. 2014 Aug 7;20(29):9759-74. doi: 10.3748/wjg.v20.i29.9759.

Abstract

Advances in genomics, molecular pathology and metabolism have generated many candidate biomarkers of colorectal cancer with potential clinical value. Epidemiological and biological studies suggest a role for adiposity, dyslipidaemia, hyperinsulinemia, altered glucose homeostasis, and elevated expression of insulin-like growth factor (IGF) axis members in the risk and prognosis of cancer. This review discusses some recent past and current approaches being taken by researches in obesity and metabolic disorders. The authors describe three main systems as the most studied metabolic candidates of carcinogenesis: dyslipidemias, adipokines and insulin/IGF axis. However, each of these components is unsuccessful in defining the diseases risk and progression, while their co-occurrence increases cancer incidence and mortality in both men and women.

Keywords: Adipokines; Colorectal cancer; Dyslipidemias; Insulin-like growth factor-system; Metabolic biomarkers; Prognosis; Risk.

Publication types

  • Review

MeSH terms

  • Adipokines / blood
  • Animals
  • Biomarkers, Tumor / blood*
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / etiology
  • Colorectal Neoplasms / pathology
  • Dyslipidemias / blood
  • Dyslipidemias / complications
  • Glucose Metabolism Disorders / blood
  • Glucose Metabolism Disorders / complications
  • Humans
  • Lipids / blood
  • Metabolomics* / methods
  • Obesity / blood
  • Obesity / complications
  • Predictive Value of Tests
  • Prognosis
  • Risk Factors
  • Somatomedins / metabolism

Substances

  • Adipokines
  • Biomarkers, Tumor
  • Lipids
  • Somatomedins